Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Blood Cancer Discovery|May 24, 2021
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIADongqing Yan, Anca Franzini, Anthony D Pomicter, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
Pageof 17